A recent study found that long-acting injectable pre-exposure prophylaxis (PrEP) is effective and safe for trans women in preventing HIV/AIDS. The new research presented at the 24th International AIDS Conference in Montreal on July 31 showed that PrEP works just as well for trans women as the treatment does for bisexual and gay men. Additionally, the report also indicated that hormone replacement therapy (HRT) had no effect on the effectiveness of PrEP, which itself has been found to reduce the risk of HIV by up to 99 percent. This has led to calls for making the drug more affordable and accessible for members of the LGBTQ+ community, notably by Grinzstejn, head of the STD/AIDS clinical research laboratory at the National Institute of Infectious Diseases in Brazil.
This article is published in Xtra Magazine.